Primidone

Anticonvulsant Barbiturate analog (deoxybarbiturate) Rx Controlled DEA Schedule II (in the US)

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog PO Initial: 5-10 mg/kg q8h; may increase gradually to 10-25 mg/kg q8h q8h (every 8 hours) Duration: Long-term; adjust based on therapeutic drug monitoring
Notes: Titrate to effect; monitor serum phenobarbital concentrations (target 15-45 µg/mL).

Clinical Indications & Species Uses

General Indications
  • Control of seizures in dogs
Dog (Canine)
  • Idiopathic epilepsy
  • Seizure disorders
  • Status epilepticus (adjunctive therapy)

Pharmacology & Mechanism of Action

Drug Class: Anticonvulsant | Pharmacological Group: Barbiturate analog (deoxybarbiturate)

Mechanism of Action: Primidone is a structural analog of phenobarbital. Its anticonvulsant activity is primarily due to its active metabolites, phenobarbital and phenylethylmalonamide (PEMA). Phenobarbital enhances GABA-mediated inhibition by binding to the GABA-A receptor, increasing chloride ion influx and hyperpolarizing neurons. PEMA contributes to anticonvulsant effects by modulating sodium channels and possibly other mechanisms. Primidone itself has some anticonvulsant activity but is less potent than its metabolites.

Pharmacodynamics: Primidone elevates the seizure threshold and reduces the spread of seizure activity. It is effective against generalized tonic-clonic and partial seizures. In dogs, it is used for the management of idiopathic epilepsy. It has sedative effects, especially during initial therapy, and can cause polyphagia and polydipsia. Chronic use may lead to tolerance and dependence.

⚡ Pharmacokinetics Summary

Absorption: Primidone is rapidly and almost completely absorbed from the gastrointestinal tract in dogs. Peak plasma concentrations occur within 1-4 hours after oral administration.
Distribution: Primidone and its metabolites distribute widely throughout the body. Phenobarbital is approximately 45-60% protein-bound in dogs. Primidone crosses the blood-brain barrier and placenta and is distributed into milk.
Metabolism: Primidone is extensively metabolized in the liver. It is oxidized to phenobarbital and hydrolyzed to PEMA. The metabolism is species-dependent; in dogs, the conversion to phenobarbital is significant, whereas in cats, it is slower and less efficient.
Excretion: Primidone and its metabolites are excreted primarily by the kidneys. In dogs, about 15-25% of the dose is excreted unchanged in urine, with the remainder as phenobarbital and PEMA. Enterohepatic recirculation may occur.
Half-Life: Dog: approximately 5-15 hours for primidone; phenobarbital half-life in dogs is 24-75 hours. Cat: primidone half-life is not well-defined but is longer due to slower metabolism.
Bioavailability: Oral bioavailability is high, approximately 90-100% in dogs.
Protein Binding: Primidone: minimal (20-30%); phenobarbital: 45-60% in dogs.

Available Formulations & Strengths

Oral Tablet 50 mg, 250 mg (PO)
Oral Suspension (compounded) Various (PO)

Contraindications & Clinical Warnings

Contraindications:
  • Known hypersensitivity to primidone or barbiturates
  • Severe hepatic insufficiency
  • Severe renal insufficiency
  • Use in cats (due to increased risk of toxicity and lack of efficacy)
  • Use in pregnant animals (teratogenic potential)
Warnings & Clinical Precautions:
  • Use with caution in animals with hepatic or renal disease
  • May cause sedation and ataxia, especially at initiation of therapy
  • Monitor for signs of hepatotoxicity (e.g., vomiting, jaundice, elevated liver enzymes)
  • Abrupt discontinuation may precipitate withdrawal seizures
  • May cause paradoxical excitement in some animals
  • Use with caution in animals with respiratory compromise
  • May interfere with diagnostic tests (e.g., thyroid function tests)

Adverse Effects & Reactions

Common:

  • Sedation
  • Ataxia
  • Polyphagia
  • Polydipsia
  • Polyuria
  • Increased liver enzymes (ALT, ALP)

Serious / Severe:

  • Hepatotoxicity
  • Blood dyscrasias (e.g., neutropenia, thrombocytopenia)
  • Stevens-Johnson syndrome (rare)
  • Exfoliative dermatitis (rare)

Rare:

  • Paradoxical hyperexcitability
  • Cerebellar degeneration (with chronic high doses)
  • Folate deficiency
  • Osteomalacia (long-term use)

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Phenobarbital Additive anticonvulsant effects and increased risk of sedation and hepatotoxicity High
Other CNS depressants (e.g., benzodiazepines, opioids) Enhanced sedation and respiratory depression Moderate
Corticosteroids Increased metabolism of corticosteroids, reducing their efficacy Moderate
Doxycycline Decreased half-life of doxycycline Mild
Griseofulvin Decreased absorption of griseofulvin Mild
Warfarin Increased metabolism of warfarin, reducing its anticoagulant effect Moderate

Overdose & Toxicity Management

Signs of Toxicity:

  • Severe sedation
  • Coma
  • Respiratory depression
  • Hypotension
  • Hypothermia
  • Pulmonary edema
  • Death

Emergency Treatment Protocol: Induce emesis if recent ingestion and animal is conscious. Administer activated charcoal. Provide supportive care: IV fluids, oxygen, mechanical ventilation if needed. Monitor vital signs and cardiac function. In severe cases, consider hemodialysis or peritoneal dialysis. No specific antidote.

Food Animal Withdrawal Times

Not approved for use in food animals. Withdrawal times not established. Do not use in animals intended for food.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F)

Handling & Special Conditions: Protect from moisture. Keep container tightly closed.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for use in dogs in the US (e.g., brand name Mylepsin).

Extra-Label (Off-Label) Use: In the US, extra-label use in food animals is prohibited due to lack of withdrawal times and potential for residues. In dogs, extra-label use is common but must comply with AMDUCA regulations.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Primidone is an effective anticonvulsant for dogs, but its use has declined due to the availability of safer alternatives like phenobarbital and levetiracetam. It is metabolized to phenobarbital, so therapeutic drug monitoring should target phenobarbital levels. Due to the risk of hepatotoxicity, periodic liver function tests are recommended. Primidone is contraindicated in cats due to severe adverse effects and poor efficacy. It is a controlled substance (Schedule II) and must be handled accordingly. Gradual withdrawal is essential to avoid withdrawal seizures.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)